Olokizumab

Unassigned

New Medicines

Moderate-to-severe rheumatoid arthritis in adults who previously failed DMARD therapy

Information

New molecular entity
R-Pharm
R-Pharm

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Humanised monoclonal antibody that selectively blocks receptor signalling of the IL-6 complex
Estimated prevalence of RA in adults England is 0.84%, equivalent to around 380,000 people [1]. Approximately 15% of RA patients have severe disease (around 60,000 people). The condition is more prevalent in women than men, with 2-3 times as many cases in women. RA can develop at any age but the typical age of onset in the UK is approximately 40-70 years, with most diagnoses made when people are in their 70s [2].
Moderate-to-severe rheumatoid arthritis in adults who previously failed DMARD therapy
Subcutaneous injection